Prognosis of a rare subtype of thyroid cancer
Spindle cell thyroid carcinoma

Zeming Liu, MD\textsuperscript{a}, Qiuyang Zhao, MD\textsuperscript{b,∗}, Wen Zeng, MD\textsuperscript{b}, Shuntao Wang, MD\textsuperscript{b}, Yiquan Xiong, MD\textsuperscript{b}, Hui Guo, MD\textsuperscript{b}, Tao Huang, MD\textsuperscript{b}, Hongtao Cheng, MD\textsuperscript{b}, Liang Guo, MD\textsuperscript{b,∗}

Abstract
Systemic illustrations of spindle cell thyroid cancer (SCTC), based on a large cohort, are few. We investigated the prognosis of SCTC compared to the most common subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Information of patients with a diagnosis of SCTC, PTC, or FTC, between 2004 and 2013, was obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Patient survival curves were investigated using Kaplan–Meier analyses, log-rank tests, and Cox proportional hazards regression analyses.

In a Kaplan–Meier analysis of the entire cohort of thyroid cancer patients, cancer specific survival declined sharply for patients with SCTC, but declined more modestly for patients with PTC and FTC. Unadjusted Cox regression analysis and Kaplan–Meier curve analysis showed that SCTC had a poorer cancer-specific mortality and all-cause mortality compared to PTC and FTC. Similar results were obtained after adjustment for different confounding factors.

Our study assessed the prognosis of SCTC, based on a large cohort, compared to PTC and FTC, and found relatively accurate hazard ratios of death rate in SCTC as compared to PTC and FTC. Thus, our findings would provide beneficial insights on patients with SCTC, and aid in treatment decision making, more radical treatment like total-thyroidectomy and/or plus central lymph node dissection should be performed for patients with SCTC.

Abbreviations: FTC = follicular thyroid cancer, PTC = papillary thyroid cancer, SCTC = spindle cell thyroid cancer, SEER = Surveillance, Epidemiology, and End Results.

Keywords: hazard ratios, prognosis, SEER, spindle cell thyroid cancer

1. Introduction
Thyroid cancer is the most common endocrine malignancy, and the incidence rate of thyroid cancer has been continuing to rise rapidly in recent decades.\textsuperscript{[1–5]} Thyroid cancer consists of several histological variants, and the common subtypes consist of papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), medullary thyroid cancer, and anaplastic thyroid cancer. Thyroid cancer also consists of many other rare subtypes, including Hürthle cell thyroid cancer, insular thyroid cancer, and spindle cell thyroid cancer.\textsuperscript{[6–10]}

Spindle cell thyroid carcinoma (SCTC) is a rare type of squamous cell carcinoma; it originates in poorly differentiated elongated epithelial cells that features as a sarcoma-like proliferation.\textsuperscript{[10,11]} Spindle cell carcinoma is found in the head and neck region including the larynx, tongue, nasal cavity, and thyroid.\textsuperscript{[10–16]}

Most previous publications focus on cases reports that represent individual features of SCTC patients.\textsuperscript{[17–20]} Systemic illustration based on a large cohort is few. Therefore, to find out the accurate hazard ratio (HR) for cancer specific mortality and all-cause mortality of this rare subtype, we analyzed the prognosis of SCTC in comparison to the most common subtypes, PTC and FTC, based on the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

2. Materials and methods
2.1. Ethics statement and database
This investigation has been conducted in accordance with the ethical standards, according to the Declaration of Helsinki, and according to national and international guidelines. It has been approved by the review board of our Hospital. We investigated SCTC, PTC, and FTC in a large cohort of patients from SEER. The SEER project is supported by the National Cancer Institute and the Centers for Disease Control and Prevention and it is a United States population-based cancer registry that began in 1973. It covers approximately 30% of the population of the United States with containing data of incidence, prevalence, mortality across multiple geographic regions.
2.2. Data collection and analysis

Patients were examined from SEER database for 2004 to 2013 with a diagnosis of STC (n = 98), PTC (n = 143439) and FTC (n = 12054) as defined by a combination of ICD-O site code of C73.9 (i.e., thyroid) from the International Classification of Diseases for Oncology (3rd edition). The following diagnostic codes were included in the study: “papillary carcinoma,” “papillary adenocarcinoma,” “spindle cell carcinoma,” “follicular adenocarcinoma,” “papillary carcinoma, follicular variant,” and “papillary and follicular adenocarcinoma.” Demographic information, age, sex, tumor size, extrathyroidal extension, multifocality, nodal metastasis, distant metastasis, surgical treatment, and radiation treatment were compiled from the SEER dataset, and a survival analysis was performed to evaluate the associations between different subtypes and prognosis.

2.3. Statistical analysis

All included patients were followed up until December 2013. The quantitative variables were expressed as mean ± standard deviation (SD), while the categorical ones were presented as percentages. The outcomes measures were thyroid carcinoma-specific mortality and all-cause mortality. Patient survival curves were investigated using Kaplan–Meier analyses, log-rank tests, and Cox proportional hazards regression analyses. HRs were used to show the magnitude of the effect of different histological subtypes on cancer-specific mortality, all-cause mortality. Around 95% CIs were used to indicate the significance of the risks. All P values were 2-sided and P < .05 was regarded as indicating statistical significance. Analyses were performed using SPSS version 23.0 (IBM Corp, Armonk, NY), Stata/SE version 12 (Stata Corp, College Station, TX), and GraphPad Prism version 6 (GraphPad Software Inc, La Jolla, CA).

3. Results

3.1. Demographic and clinical features

The baseline characteristics (demographic data, clinicopathological features, and treatment) were compared between SCTC, and PTC, FTC (Table 1). The mean durations of survival during the study period were 19.39, 97.1, 2 and 123.79 months for SCTC, PTC, and FTC, respectively. Mean age was higher in patients with SCTC than with PTC (69.09 ± 14.09 vs 48.14 ± 15.66 years, P < .001) and FTC (69.09 ± 14.09 vs 30.64 ± 17.61 years, P < .001, Table 1).

3.2. Cancer-specific and all-cause mortality rates for different histological subtypes

In the study cohort, the cancer-specific mortality rate, per 1000 person-years, for SCTC, PTC, and FTC were 410.526 [95% confidence interval (CI), 321.931–523.504], 2.336 (95% CI, 2.249–2.425), and 6.031 (95% CI, 5.612–6.481), respectively (Table 2). The all-cause mortality, per 1000 person-years, in patients with SCTC, PTC, and FTC were 486.315 (95% CI, 388.969–608.025), 12.374 (95% CI, 12.173–12.579) and 22.347 (95% CI, 21.528–23.198), respectively (Table 2).

On comparing PTC and FTC versus SCTC patients, the HRs for cancer-specific deaths were 0.008 (95% CI, 0.007–0.011) and 0.024 (95% CI, 0.019–0.031), respectively. After adjustment for demographic data: age at diagnosis, race, gender, the HRs for cancer-specific deaths of PTC and FTC were 0.007 (95% CI,
Histological types Unadjusted Cox regression Adjusted 1 Cox regression Adjusted 2 Cox regression Adjusted 3 Cox regression
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
SCTC Ref 0.008 (0.007–0.011) <.001 0.007 (0.001–0.054) <.001 0.009 (0.000–0.866) .043 0.097 (0.012–0.808) .031
PTC 0.024 (0.019–0.031) <.001 0.085 (0.046–0.159) <.001 0.143 (0.040–0.517) .003 0.010 (0.000–5.225) .150
FCT Ref 0.029 (0.023–0.035) <.001 0.065 (0.035–0.124) <.001 0.037 (0.005–0.288) .002 0.087 (0.011–0.710) .023

FCT = follicular thyroid carcinoma, PTC = papillary thyroid cancer, SCTC = spindle cell thyroid carcinoma.

Adjustment 1 was made for patient age at diagnosis, race, gender.
Adjustment 2 was made for patient age at diagnosis, race, gender, TNM stage, multifocality, extension, radiation and surgery treatment.
Adjustment 3 was made for patient age at diagnosis, race, gender, TNM stage, multifocality, extension, radiation and surgery treatment.

Histological types Cancer-specific deaths, % Cancer-specific deaths per 1000 person-years 95% CI All cause deaths, % All cause deaths per 1000 person-years 95% CI
SCTC 77 78.57 410.526 321.931–523.504 90 91.83 486.315 388.969–408.025
PTC 2798 1.95 2.336 2.249–2.425 15842 11.04 12.374 12.173–12.579
FCT 787 6.53 6.031 5.612–6.481 2957 24.53 22.347 21.528–23.198

FTC = follicular thyroid carcinoma, PTC = papillary thyroid cancer, SCTC = spindle cell thyroid carcinoma.

Adjustment 1 was made for patient age at diagnosis, race, and gender.
Adjustment 2 was made for patient age at diagnosis, race, gender, TNM stage, multifocality, extension.
Adjustment 3 was made for patient age at diagnosis, race, gender, TNM stage, multifocality, extension, radiation, and surgery treatment.

Histologically, spindle cells have a fusiform appearance and are always arranged with the intersecting fascicles.\[^{15,20,21}\] Spindle cell tumors of the thyroid gland are rare. Due to the rarity of the tumors, the cell biology and prognosis of spindle cells in thyroid gland tumors are not fully understood. In previous case reports, most scholars support the fact that the spindle cells of the thyroid glands may represent a metaplastic transformation of the follicular cells because of the expression of thyroglobulin.\[^{15,20,21}\]

### 4. Discussion

Histologically, spindle cells have a fusiform appearance and are always arranged with the intersecting fascicles. \[^{15,20,21}\] Spindle cell tumors of the thyroid gland are rare. Due to the rarity of the tumors, the cell biology and prognosis of spindle cells in thyroid gland tumors are not fully understood. In previous case reports, most scholars support the fact that the spindle cells of the thyroid glands may represent a metaplastic transformation of the follicular cells because of the expression of thyroglobulin.\[^{15,20,21}\]
Sophie et al. have reported a spindle cell follicular carcinoma of the thyroid gland and suggested that more clinical, histopathological, molecular, and prognostic studies of spindle cell thyroid cancer are needed for a better comparison with the more conventional thyroid tumors.[15] However, until now, there are no systematic descriptions of SCTC due to the small number cases from single institutions.

In this study, however, we collected and included a large cohort of patients with SCTC from the SEER database. This made up for the deficiency of small sample size. In our study, SCTC presents with aggressive clinicopathological characteristics compared to PTC and FTC. TNM system for stage and extension, Cox regression analysis, and Kaplan Meier curve analysis showed that SCTC had a poorer cancer-specific mortality and all-cause mortality compared to PTC and FTC.

In our study, we found similar results, even after excluding the confounding factors. For all-cause mortality, after adjustment of demographic data, clinicopathological features, and treatment approaches, patients with SCTC still had poorer prognosis than those with PTC and FTC. Regarding all-cause deaths, SCTC showed poorer prognosis than PTC after adjustment for different variants. However, the difference in values between SCTC and FTC, after adjustments for all confounding factors (including treatment), reduced. This may due to the varied sample status and the large 95% CI span.

One interesting finding was that 1000 person-years cancer-specific deaths and 1000 person-years all-cause deaths of SCTC had similar values (410.526 vs. 486.315), indicating that mortality of patients with SCTC was mostly due to cancer-specific reasons and not other causes such as nephrotic syndrome, and diseases of the heart, lung and bronchus. In other words, SCTC is an aggressive malignancy that could directly cause mortality itself without the role of other factors.

Molecular makers play an important role in diagnosis and prognosis of thyroid cancers.[21–25] Cytological examination of fine-needle aspiration biopsy is often misdiagnosed.[17] However, molecular markers help in distinguishing the histological subtypes. For example, high Mib-1 proliferation index, elevated levels of circulating serotonin and chomogranin-A, and p53 positivity favors the diagnosis of malignancies of epithelial origin,[17,26] but CD34, S-100, and calcitonin are often absent in spindle cells.[21] Unfortunately, the SEER database could not record data for these molecular markers in spindle cell thyroid cancer; therefore, systematic molecular mechanisms still need to be confirmed in future works.

This study has some limitations worth mentioning, though multivariate analysis was performed to account for confounding factors. First, overestimation bias may have been introduced by designation of only mortality rates, and a lack of data on recurrence. Furthermore, molecular markers such as thyroid

![Figure 1. Kaplan–Meier curves among patients stratified by subtype for cancer-specific survival (A–C).](image)

![Figure 2. Kaplan–Meier curves among patients stratified by subtype for all-cause survival (A–C).](image)
transcription factor-1, cytokeratin 19, and CD34 antigen, which may play an important role in assessment of diagnosis and prognosis of SCTC,\(^{15,21}\) were not evaluated in this study. In addition, as the SEER database focuses on gathering reliable information during the diagnostic period, limited information was available on later events.

To summarize, our study, based on a large cohort, assessed the prognosis of SCTC in comparison to PTC and FTC, and found relatively accurate hazard ratios of death rate in SCTC as compared to PTC and FTC. Thus, our findings would provide beneficial insights on patients with SCTC, and aid in treatment decision-making, more radical treatment like total-thyroidectomy and/or plus central lymph node dissection should be performed for patients with SCTC.

**Author contributions**

**Data curation:** Qiuyang Zhao.

**Formal analysis:** Qiuyang Zhao, Shuntao Wang.

**Funding acquisition:** Hui Guo, Tao Huang.

**Methodology:** Zeming Liu, Wen Zeng, Yuquan Xiong, Hongtao Cheng.

**Project administration:** Zeming Liu, Tao Huang.

**Resources:** Zeming Liu, Wen Zeng, Shuntao Wang, Hongtao Cheng.

**Software:** Qiuyang Zhao.

**Supervision:** Zeming Liu, Liang Guo.

**Validation:** Hui Guo, Tao Huang.

**Visualization:** Zeming Liu.

**Writing – original draft:** Qiuyang Zhao, Hongtao Cheng.

**Writing – review & editing:** Zeming Liu, Tao Huang.

Tao Huang: 0000-0001-6722-9158.

**References**

[1] Fahiminiya S, De KL, Foulkes WD. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016;375:1054.

[2] Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the United States. Endocr Rel Cancer 2016;23:313.

[3] Md HB, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:133.

[4] Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017;317:1338–48.

[5] Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 2015;101:1c20152917.

[6] Chindris AM, Casler JD, Bernet VJ, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid. Clin Endocrinol Metab 2015;100:55–62.

[7] Mishra AK, Agawal A, Mishra SK. Insular carcinoma; subtype of thyroid cancer with aggressive clinical course. World J Surg 2005;29:410–411.

[8] Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival. Cancer 2012;118:3260.

[9] Rogers JD, Lindberg RD, Hill CS Jr, et al. Spindle and giant cell carcinoma of the thyroid: a different therapeutic approach. Cancer 1974;34:1328–32.

[10] Su HH, Chu ST, Hou YY, et al. Spindle cell carcinoma of the oral cavity and oropharynx: factors affecting outcome. J Chin Med Assoc 2006;69:478–83.

[11] Kim TH, Kim CH. Spindle cell carcinoma of the tongue combined with double primary cancer of the thyroid gland: a case report. J Korean Assoc Oral Maxillofac Surg 2016;42:221–6.

[12] Patten DK, Ahmed A, Greaves O, et al. Anaplastic spindle cell squamous carcinoma arising from tall cell variant papillary carcinoma of the thyroid gland: a case report and review of the literature. Case Rep Endocrinol 2017;2017:1–5.

[13] Al Rasheed MRH, Acosta A, Tarjan G. Encapsulated follicular variant of papillary thyroid carcinoma/noninvasive follicular thyroid neoplasm with papillary-like nuclear features with Spindle Cell Metaplasia: case report and review of literature. J Cutan Pathol 2016;43:252–7.

[14] Giusiano-Courcambeck S, Denizot A, Secq V, et al. Pure spindle cell follicular carcinoma of the thyroid. Thyroid 2008;18:1023.

[15] Park YW, Clarke RE. Spindle cell carcinoma of the larynx with simultaneous carcinoma of the thyroid gland. Am J Otolaryngol 1993;14:350–3.

[16] Corrado S, Corsello SM, Maiorana A, et al. Papillary thyroid carcinoma with predominant spindle cell component: report of two rare cases and discussion on the differential diagnosis with other spindle thyroid neoplasms. Endocr Pathol 2014;25:307–14.

[17] Woenschhaus C, Cameselle-Teijeiro J, Ruiz-Ponte C, et al. Spindle cell variant of papillary thyroid carcinoma. Histopathology 2004;45:424–7.

[18] Brandwein-Gensler MS, Wang BY, Urken ML. Spindle cell transformation of papillary carcinoma: an aggressive entity distinct from anaplastic thyroid carcinoma. Arch Pathol Lab Med 2004;128:87–9.

[19] JoAnne Vergilio , Baloch ZW, Livolsi VA. Spindle cell metaplasia of the thyroid arising in association with papillary carcinoma and follicular adenoma. Am J Clin Pathol 2002;117:199–204.

[20] Ma X, Xia C, Liu H, et al. Primary thyroid spindle cell tumors: spindle cell variant of papillary thyroid carcinoma? Int J Clin Exp Pathol 2015;8:13528.

[21] Liu Z, Li X, Shi L, et al. Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Pathol 2014;7:2304.

[22] Liu C, Chen T, Liu Z. Associations between BRAF V600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol 2016;14:241.

[23] Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duel of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol 2016; doi: 10.1001/jamaoncol.2016.3288. [Epub ahead of print].

[24] Liu Z, Yu P, Xiong Y, et al. Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. Int J Clin Exp Med 2015;8:4369.

[25] Laforga JB, Aranda FI. Pseudoangiosarcomatous features in medullary thyroid carcinoma spindle-cell variant. Report of a case studied by FNA and immunohistochemistry. Diagn Cytopathol 2007;35:424–8.